+359 886 516 705 office@healthpr.bg

You need a license to cut-and-paste this copyrighted news content.
Use this link to purchase your paid subscription ($200/year for individuals and $1,000/year for companies of every size): https://endpts.com/subscribe
Already a paid subscriber? Sign in to Endpoints News to remove this message.

If there’s one law in oncology R&D, it’s that you don’t cross FDA cancer czar Richard Pazdur. Pazdur is famous for cutting companies to shreds during panel reviews if they come to the agency with questionable data after straying from the path he set for them. 

A blunt speaker, Pazdur tends to deliver on what he says. When he stood up at ASCO several years ago to say that the breakthrough therapy designation was important and that the agency would start hustling along accelerated reviews for cancer patients, he delivered on every word — spurring a revolution in the way cancer drug trials are designed and executed and influencing the entire field of research and development.

Read more here.